Organon (OGN) Divestments (2020 - 2026)

Organon (OGN) posted quarterly Divestments of $433.0 million for Q1 2026, up 43200.0% on a QoQ basis from $1.0 million in Q4 2020.

Organon (OGN) Divestments (2020 - 2026) Analysis & Trends

Organon (OGN) has reported Divestments for 2 consecutive years, with $433.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Divestments changed N/A year-over-year to $433.0 million; the TTM figure through Mar 2026 stood at $433.0 million (changed N/A YoY), while the FY2020 annual figure was -$8.0 million, up 42.86% from the prior year.
Divestments came in at $433.0 million for Q1 2026 at Organon, up from $1.0 million in the prior quarter.
The five-year high for Divestments was $433.0 million in Q1 2026, with the low at $433.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	-
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	-
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	-
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-2.00 Mn
10	Organon	3.53 Bn	2.41 Bn	783.00 Mn	433.00 Mn

Download Data